久留米大学研究者紹介

【詳細】
  •  タイトル

  •  種類 / 単著・共著等 / 発行・発表年
     発行所、発行・発表雑誌等の名称 / 巻号頁

  • 山田  亮の著書・論文・学会発表等
    No. 詳細
    1

  • Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
  • 雑誌 / 共著 / 2020年 6月
    Int J Oncol.
  • / Vol.56 No.6 1479-1489.
  • 2

  • Integrity of plasma DNA is inversely correlated with vaccine-induced anti-tumor immunity in ovarian cancer patients.
  • 雑誌 / 共著 / 2020年 5月
    Cancer Immunol Immunother.
  • / doi: 10.1007/s00262-020-02599-4.
  • 3

  • Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
  • 雑誌 / 共著 / 2020年 2月
    Cancer Immunol Immunother
  • / doi: 10.1007/s00262-020-02498-8.
  • 4

  • The CD4/CD8 ratio is a prognostic factor in IgG non-responders among peptide vaccine treated ovarian cancer patients.
  • 雑誌 / 共著 / 2020年 1月
    Cancer Sci,
  • / doi: 10.1111/cas.14349.
  • 5

  • Identification of dominant T-cell epitopes in the major Japanese cypress pollen allergen Cha o 3.
  • 雑誌 / 共著 / 2019年 8月
    Allergol Int.
  • / Vol.S1323-8930 No.19 30109-1
  • 6

  • A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
  • 雑誌 / 共著 / 2019年 2月
    Neuro Oncol.
  • / Vol.21 No.3 348-359
  • 7

  • Identification of Cha o 3 homolog Cry j 4 from Cryptomeria japonica (Japanese cedar) pollen: Limitation of the present Japanese cedar-specific ASIT.
  • 雑誌 / 共著 / 2018年10月
    Allergol Int.
  • / Vol.67 No.4 467-474
  • 8

  • Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
  • 雑誌 / 共著 / 2018年 9月
    Cancer Sci.
  • / Vol.109 No.9 2660-2669
  • 9

  • Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.
  • 雑誌 / 共著 / 2017年12月
    Cancer Sci.
  • / Vol.108 No.12 2326-2332.
  • 10

  • Clinical Impact of Tumor-Infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma.
  • 雑誌 / 共著 / 2017年11月
    Ann Surg Oncol.
  • / Vol.24 No.12 763-3770
  • 11

  • Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
  • 雑誌 / 共著 / 2017年11月
    Clin Lung Cancer
  • / Vol.18 No.6 e385-e394
  • 12

  • Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
  • 雑誌 / 共著 / 2017年 9月
    Cancer Sci.
  • / Vol.108 No.9 1732-1738
  • 13

  • A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
  • 雑誌 / 共著 / 2017年 5月
    Cancer Sci.
  • / Vol.108 No.5 838-845
  • 14

  • Immunological evaluation of peptide vaccination for cancer patients with the HLA-A11+ or -A33+ allele.
  • 雑誌 / 共著 / 2017年 4月
    Cancer Sci.
  • / Vol.108 No.4 598-603
  • 15

  • Single nucleotide polymorphisms of the Haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination.
  • 雑誌 / 共著 / 2017年
    Oncol Letter
  • / Vol.2017 No.13 993-999
  • 16

  • Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.
  • 雑誌 / 共著 / 2017年
    J Immunol Res.
  • / Vol.2017 No.2017 1423683
  • 17

  • Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
  • 雑誌 / 共著 / 2016年10月
    Cancer Immunol Immunother.
  • / Vol.65 No.10 1223-31
  • 18

  • Identification and gene of new major allergen Cha o 3 from Chamaecyparis obtusa (Japanes Cypress) pollen.
  • 雑誌 / 共著 / 2016年 9月
    J Allergy Clin Immunol.
  • / Vol.138 No.3 911-913
  • 19

  • A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
  • 雑誌 / 共著 / 2016年 7月
    Eur Urol.
  • / Vol.70 No.1 35-41
  • 20

  • Randomized phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients with previously treated advanced wild type EGFR non-small-cell lung cancer.
  • 雑誌 / 共著 / 2016年 5月
    J Immunol Res.
  • / Vol.2016 No.2016 1745108
  • 21

  • Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients.
  • 雑誌 / 共著 / 2016年 5月
    Cancer Science
  • / Vol.107 No.5 590-600
  • 22

  • A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
  • 雑誌 / 共著 / 2016年 2月
    Cancer Immunol Immunother.
  • / Vol.65 No.2 151-60
  • 23

  • An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
  • 雑誌 / 共著 / 2016年 1月
    Clin Cancer Res.
  • / Vol.22 No.1 54-60
  • 24

  • Blockade of High Mobility Group Box 1 (HMGB1) augments anti-tumor T-cell response induced by peptide vaccination as a co-adjuvant.
  • 雑誌 / 共著 / 2016年
    Cancer Sci.
  • / Vol.107 No.12 1721-1729
  • 25

  • Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer.
  • 雑誌 / 共著 / 2016年
    Evid Based Complement Alternat Med.
  • / Vol.2016 No.2016 5929525
  • 26

  • Phase II study of personalized peptide vaccination with both a hepatitis C virus (HCV)-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients.
  • 雑誌 / 共著 / 2015年10月
    J Immunol Res.
  • 27

  • Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
  • 雑誌 / 共著 / 2015年10月
    Cancer Sci.
  • / Vol.106 No.10 1257-63
  • 28

  • Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
  • 雑誌 / 共著 / 2015年 9月
    Cancer Sci.
  • / Vol.106 No.9 1111-7
  • 29

  • Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination.
  • 雑誌 / 共著 / 2015年 9月
    Hum Vaccin Immunother
  • 30

  • Identification of Novel Lck-derived T Helper Epitope Long Peptides Applicable for HLA-A2+ Cancer Patients as Cancer Vaccine.
  • 雑誌 / 共著 / 2015年 8月
    Cancer Sci.
  • 31

  • Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
  • 雑誌 / 共著 / 2015年 4月
    Cancer Immunol Immunother
  • / Vol.64 No.4 493-505
  • 32

  • Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
  • 雑誌 / 共著 / 2015年 1月
    Int J Oncol.
  • / Vol.46 No.1 55-62
  • 33

  • Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer.
  • 雑誌 / 共著 / 2014年12月
    Cancer Immunol Res.
  • / Vol.2 No.12 1154-62
  • 34

  • PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer.
  • 雑誌 / 共著 / 2014年10月
    Cancer Sci.
  • / Vol.105 No.10 1229-35
  • 35

  • Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
  • 雑誌 / 共著 / 2014年 6月
    Immunopharmacol Immunotoxicol.
  • / Vol.36 No.3 224-36
  • 36

  • Personalized Peptide Vaccine for Treatment of Advanced Cancer.
  • 雑誌 / 共著 / 2014年 2月
    Curr Med Chem.
  • 37

  • The influence of Chlorella and its hot water extract supplementation on quality of life in patients with breast cancer.
  • 雑誌 / 共著 / 2014年
    Evid Based Complement Alternat Med.
  • 38

  • A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
  • 雑誌 / 共著 / 2013年12月
    BMC Cancer.
  • / Vol.13 613
  • 39

  • A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
  • 雑誌 / 共著 / 2013年 9月
    Oncol Rep.
  • / Vol.30 No.3 1094-100
  • 40

  • Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases.
  • 雑誌 / 共著 / 2013年 9月
    Dev Comp Immunol.
  • / Vol.41 No.1 68-76
  • 41

  • Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine.
  • 雑誌 / 共著 / 2013年 6月
    Evid Based Complement Alternat Med.
  • 42

  • Current status of immunotherapy for the treatment of biliary tract cancer.
  • 雑誌 / 共著 / 2013年 5月
    Hum Vaccin Immunother.
  • / Vol.9 No.5 1069-72
  • 43

  • The next generation of peptide vaccines for advanced cancer.
  • 雑誌 / 共著 / 2013年 1月
    Cancer Sci
  • / Vol.104 No.1 15-21
  • 44

  • Controversies in Clinical Trials of Cancer Vaccines for Glioblastoma.
  • 雑誌 / 共著 / 2013年
    J Vaccines Vaccin.
  • / Vol.4 171
  • 45

  • In vitro induction of specific CD8+ T lymphocytes by tumor-associated antigenic peptides in patients with oral squamous cell carcinoma.
  • 雑誌 / 共著 / 2012年 9月
    Cancer Lett
  • / Vol.322 No.1 86-91
  • 46

  • Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.
  • 雑誌 / 共著 / 2012年 9月
    Hum Vaccin Immunother.
  • / Vol.8 No.9
  • 47

  • Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
  • 雑誌 / 共著 / 2012年 7月
    Prostate
  • / Vol.72 No.8 834-45
  • 48

  • Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination.
  • 雑誌 / 共著 / 2012年 7月
    Cancer
  • / Vol.118 No.12 3208-21
  • 49

  • Immunological Evaluation of Personalized Peptide Vaccination in Refractory Small Cell Lung Cancer.
  • 雑誌 / 共著 / 2012年 4月
    Cancer Sci.
  • / Vol.103 No.4 638-44
  • 50

  • Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status, and pre-existing antigen -specific immunity as possible biomarkers for patient prognosis.
  • 雑誌 / 共著 / 2012年
    Experimental and Therapeutic Medicine
  • / Vol.3 463-469
  • 51

  • Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
  • 雑誌 / 共著 / 2012年
    Int J Oncol
  • / Vol.40 1492-1500
  • 52

  • A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer.
  • 雑誌 / 共著 / 2011年 4月
    Prostate.
  • / Vol.71 No.5 470-9
  • 53

  • Phase I trial of a personalized Peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
  • 雑誌 / 共著 / 2011年 1月
    J Clin Oncol.
  • / Vol.29 No.3 337-44
  • 54

  • Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.
  • 雑誌 / 共著 / 2011年 1月
    Cancer Biol Ther.
  • / Vol.10 No.12 1266-79
  • 55

  • Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases.
  • 雑誌 / 共著 / 2011年 1月
    Oncol Report.
  • / Vol.25 No.1 57-62
  • 56

  • Phase-I clinical study of a personalized peptide vaccination available for six different HLA (HLA-A2, -A3, -A11, -A24, -A31, and -A33)-positive patients with advanced cancer.
  • 雑誌 / 共著 / 2011年
    Exp Ther Med.
  • / Vol.2 109-117
  • 57

  • A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.
  • 雑誌 / 共著 / 2010年12月
    BJU Int.
  • 58

  • Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination.
  • 雑誌 / 共著 / 2010年10月
    Cancer Sci.
  • / Vol.101 No.10 2110-4
  • 59

  • A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
  • 雑誌 / 共著 / 2010年 9月
    Oncol Rep.
  • / Vol.24 No.3 795-801
  • 60

  • Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines.
  • 雑誌 / 共著 / 2010年 7月
    Eur J Cancer
  • / Vol.46 No.9 1514-9
  • 61

  • A randomized phase II trial of personalized peptide vaccine plus low dose estramustine (EMP) versus standard dose EMP in patients with hormone refractory prostate cancer.
  • 雑誌 / 共著 / 2010年 7月
    Cancer Immunol. Immunother.
  • / Vol.59 No.7 1001-9
  • 62

  • Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines.
  • 雑誌 / 共著 / 2010年 6月
    Eur J Cancer.
  • / Vol.46 No.9 1514-9
  • 63

  • Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
  • 雑誌 / 共著 / 2009年11月
    Cancer Immunol. Immunother.
  • / Vol.58 No.11 1843-52
  • 64

  • Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different HLA-class I-A alleles.
  • 雑誌 / 共著 / 2009年10月
    Cancer Science.
  • / Vol.100 No.10 1935-42
  • 65

  • A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients infected with HCV with various HLA class IA allele.
  • 雑誌 / 共著 / 2009年 7月
    J. Med. Virol.
  • / Vol.81 No.7 1232-40
  • 66

  • Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
  • 雑誌 / 共著 / 2009年 6月
    Lung Cancer.
  • / Vol.64 No.3 326-33
  • 67

  • Recent advances in cancer vaccines: an overview.
  • 雑誌 / 共著 / 2009年 2月
    Jpn J Clin Oncol.
  • / Vol.39 No.2 73-80
  • 68

  • Recent advances in cancer vaccines: an overview.
  • 雑誌 / 共著 / 2009年 2月
    Jpn J Clin Oncol
  • / Vol.39 No.2 73-80
  • 69

  • Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.
  • 雑誌 / 共著 / 2008年
    Oncol. Report
  • / Vol.19 No.5 1277-83
  • 70

  • EphB6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in HLA-A2+ glioma patients.
  • 雑誌 / 共著 / 2008年
    Cancer Sci.
  • / Vol.99 No.8 1656-62
  • 71

  • A randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms.
  • 雑誌 / 共著 / 2008年
    Asian J. Androl.
  • / Vol.10 No.5 777-85
  • 72

  • Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients.
  • 雑誌 / 共著 / 2008年
    Prostate
  • / Vol.68 No.16 1753-62
  • 73

  • Peptide encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G is a cancer antigen recognized by cytotoxic T lymphocytes. In “FRAGILE SITES: New discoveries and changing perspectives”
  • 単行本 / 分担執筆 / 2007年
    Eds: Isabel Arrieta, Olga Penagarikano, and Mercedes Telez. Nova Science Publishers Inc. Hauppauge NY.
  • / 261-270
  • 74

  • HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
  • 雑誌 / 共著 / 2007年
    Oncol Report
  • / Vol.18 No.6 1463-1468
  • 75

  • Serum levels of IgG to the peptide of HCV-1b core at positions 35-44 correlated with persistent infection, while levels f IgG to the peptide of NS5A at position 2132-2140 correlated with better prognosis in HCV-infected patients.
  • 雑誌 / 共著 / 2007年
    Medical Microbiol. Immunol.
  • / Vol.196 No.3 157-164
  • 76

  • Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
  • 雑誌 / 共著 / 2007年
    Caner Science
  • / Vol.98 No.4 605-611
  • 77

  • Identification of target antigens in specific immunotherapy for renal cell carcinoma.
  • 雑誌 / 共著 / 2007年
    J Urol.
  • / Vol.177 No.3 1157-1162
  • 78

  • Phase 1 clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
  • 雑誌 / 共著 / 2007年
    Vaccine
  • / Vol.25 7429-7435
  • 79

  • Excision Repair Cross-Complementation Group 1 Predicts Progression-Free and Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
  • 雑誌 / 共著 / 2007年
    Cancer Science
  • / Vol.98 No.9 1336-1343
  • 80

  • Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
  • 雑誌 / 共著 / 2007年
    Br. J. Cancer
  • / Vol.97 No.12 1648-1654
  • 81

  • Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
  • 雑誌 / 共著 / 2007年
    Cancer Science
  • / Vol.98 No.7 1113-1119
  • 82

  • Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment.
  • 雑誌 / 共著 / 2007年
    Oncology Research
  • / Vol.16 No.7 341-349
  • 83

  • Expression of APOBEC3G in kidney cells.
  • 雑誌 / 共著 / 2007年
    Tissue Antigen
  • / Vol.69 No.1 95-98
  • 84

  • Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b that can induce both cellular and humoral immunity in HCV1b+ HLA-A24+ patients.
  • 雑誌 / 共著 / 2007年
    Hepatol. Res
  • / Vol.37 86-195
  • 85

  • Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b that can induce both cellular and humoral immunity in HCV1b+ HLA-A24+ patients.
  • 雑誌 / 共著 / 2007年
    Hepatol. Res.
  • / Vol.37 186-195
  • 86

  • A new epitope peptide derived from hepatitis C virus (HCV) 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31 and -A33.
  • 雑誌 / 共著 / 2007年
    Cancer Immunol. Immunother.
  • / Vol.56 1359-1366
  • 87

  • A Phase I Trial of Personalized Peptide Vaccination for Cytokine-refractory Metastatic Renal Cell Carcinoma Patients.
  • 雑誌 / 共著 / 2007年
    Cancer Sci.
  • / Vol.98 No.12 1965-1968
  • 88

  • Nonmutated Self-Antigen-Derived Cancer Vaccine Peptides Elicit an IgE-Independent but Mast Cell-Dependent Immediate-Type Skin Reaction without Systemic Anaphylaxis.
  • 雑誌 / 共著 / 2006年
    J Immunol.
  • / Vol.176 No.2 857-63
  • 89

  • Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients.
  • 雑誌 / 共著 / 2006年
    Oncol Rep.
  • / Vol.15 No.2 317-21
  • 90

  • Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
  • 雑誌 / 共著 / 2006年
    Int J Oncol.
  • / Vol.29 No.6 1555-1560
  • 91

  • High expression of APOBEC3G in patients infected with hepatitis C virus.
  • 雑誌 / 共著 / 2006年
    J Mol Histol.
  • / Vol.37 No.8-9 327-332
  • 92

  • Personalized peptide vaccines: A new therapeutic modality for cancer.
  • 雑誌 / 共著 / 2006年
    Cancer Sci.
  • / Vol.97 No.10 970-976
  • 93

  • New epitope peptides derived from hepatitis C virus(HCV) 2a which have the capacity to induce cytotoxic T lymphocytes in HLA-A2+ HCV-infected patients.
  • 雑誌 / 共著 / 2006年
    Microbiol Immunol.
  • / Vol.50 No.11 857-865
  • 94

  • Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
  • 雑誌 / 共著 / 2006年
    Cell Immunol.
  • / Vol.241 No.1 38-46
  • 95

  • Anti-tumor effects of systemic and local immunization with a cytotoxic T lymphocyte-directed peptide in combination with a local injection of OK-432.
  • 雑誌 / 共著 / 2006年
    Clin Cancer Res.
  • / Vol.12 No.4 1325-32
  • 96

  • Immunological and clinical evaluation of personalized peptide vaccination for Patients with advanced malignant glioma.
  • 雑誌 / 共著 / 2005年
    Clin Cancer Res.
  • / Vol.11 No.16 5900-11.
  • 97

  • Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b+ HLA-A24+ patients.
  • 雑誌 / 共著 / 2005年
    Hepatol Res.
  • / Vol.32 No.4 227-34
  • 98

  • Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer.
  • 雑誌 / 共著 / 2005年
    Oncol Rep.
  • / Vol.13 875-83
  • 99

  • Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with non-prostate adenocarcinoma.
  • 雑誌 / 共著 / 2005年
    J Immunother.
  • / Vol.28 No.6 535-41
  • 100

  • Immunological evaluation of vaccination of peptides derived from epithelial cancer-related antigens in two patients with hematological malignancy.
  • 雑誌 / 共著 / 2005年
    Int J Oncol.
  • / Vol.26 1605-12
  • 101

  • Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24(+) HRPC patients.
  • 雑誌 / 共著 / 2005年
    Prostate.
  • / Vol.63 1-12
  • 102

  • Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers.
  • 雑誌 / 共著 / 2004年
    J. Immunother.
  • / Vol.27 60-67
  • 103

  • T cell receptor Vb gene usage by T cells reactive with the tumor rejection antigen SART-1 in oral squamous cell carcinoma.
  • 雑誌 / 共著 / 2004年
    Int. J. Cancer
  • / Vol.108 686-695
  • 104

  • A phase I trial of CTL-purecursor-oriented peptide vaccine for colorectal carcinoma patients.
  • 雑誌 / 共著 / 2004年
    Br. J. Cancer
  • / Vol.90 1334-1342
  • 105

  • Immunological monitoring during combination of patient-oriented peptide vaccination and estramustin phosphate I patients with metastatic hormone refractory prostate cancer.
  • 雑誌 / 共著 / 2004年
    Prostate
  • / Vol.60 32-45
  • 106

  • Analysis of cellular localization of SART3 tumor antigen by newly established monoclonal antibody: Heterotopic expression of SART3 tumor antigen on the surface of B-lineage leukemic cells.
  • 雑誌 / 共著 / 2004年
    Oncol. Reports
  • / Vol.11 785-789
  • 107

  • Natural antibodies reactive to self peptides which had been identified as cytotoxic T-lymphocyte (CTL)-directed tumor antigens.
  • 雑誌 / 共著 / 2004年
    Immunobiology.
  • / Vol.209 245-253
  • 108

  • Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides besed on pre-existing peptide-specific cellular responses.
  • 雑誌 / 共著 / 2004年
    Clin. Cancer Res.
  • / Vol.10 929-937
  • 109

  • Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer.
  • 雑誌 / 共著 / 2004年
    Cancer Sci.
  • / Vol.95 77-84
  • 110

  • Peptide-based vaccines for cancer immunotherapy. In "Current Topics in Peptide & Protein Research"
  • 単行本 / 分担執筆 / 2004年
    Research Trend, India
  • / Vol.6 71-80
  • 111

  • Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of inducing HLA-A2 rstricted cytotoxic T lymphocytes is detectable in the majority of HCV-infected individuals without HLA-A2 restriction.
  • 雑誌 / 共著 / 2004年
    Microbiol. Immunol.
  • / Vol.48 507-517
  • 112

  • Immunological evaluation of pre-designated vaccination of the peptides frequently vaccinated to cancer patients in an individualized peptide regimen.
  • 雑誌 / 共著 / 2004年
    Int. J. Oncol.
  • / Vol.25 121-131
  • 113

  • Peptide vaccination for patients with melanoma and other types of cancers based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in the periphery.
  • 雑誌 / 共著 / 2003年
    J. Immunother.
  • / Vol.26 357-366
  • 114

  • Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the Hela epithelial cell line.
  • 雑誌 / 共著 / 2003年
    Microbiol. Immunol.
  • / Vol.47 775-783
  • 115

  • Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.
  • 雑誌 / 共著 / 2003年
    Cancer Sci.
  • / Vol.94 802-808
  • 116

  • Identification of cytotoxic T lymphocyte-directed epitope encoded by an intron of putative tumor suppresser gene Testin of the common fragile site 7G region at 7q31.2: Peptide vaccine candidate for HLA-B52+ and -62+ cancer patients.
  • 雑誌 / 共著 / 2003年
    Eur. J. Immunol.
  • / Vol.33 2964-2973
  • 117

  • Identification of ribosomal proteins S2 and L10a as tumor-rejection antigens recognized by HLA-A26-restricted CTL.
  • 雑誌 / 共著 / 2003年
    Tissue Antigens
  • / Vol.61 136-145
  • 118

  • Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients
  • 雑誌 / 共著 / 2003年
    Cancer Sci.
  • / Vol.94 548-556
  • 119

  • Gene and peptide analyses of newly defined lung cancer rejection antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes.
  • 雑誌 / 共著 / 2003年
    Cancer Res.
  • / Vol.63 2829-2835
  • 120

  • IgG reactive to CTL-directed epitope peptides is either lacking or unbalanced in atopic dermatitis patients.
  • 雑誌 / 共著 / 2003年
    Tissue Antigens
  • / Vol.61 352-361
  • 121

  • Induction fo cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
  • 雑誌 / 共著 / 2003年
    Prostate
  • / Vol.57 80-92
  • 122

  • UDP-Gal: bGlcNAc b1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumor antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumor.
  • 雑誌 / 共著 / 2002年
    Br. J. Cancer
  • / Vol.87 1006-1012
  • 123

  • Development of peptide-based vaccines for epithelial cancer. In "Research Progress in Cancer 2"
  • 単行本 / 分担執筆 / 2002年
    Global Research Network, India.
  • / 241-247
  • 124

  • Simple assay for antitumor immuno-active glycoprotein derived from Chlorella vulgaris strain CK22 using ELISA
  • 雑誌 / 共著 / 2002年
    Phytother. Res.
  • / Vol.16 581-585
  • 125

  • Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals.
  • 雑誌 / 共著 / 2002年
    Tissue Antigens
  • / Vol.59 259-272
  • 126

  • Cellular and humoral immune responses to tumor cells and peptides in lung cancer patients vaccinated with cyclophilinB peptide.
  • 雑誌 / 共著 / 2002年
    J. Immunother.
  • / Vol.25 439-444
  • 127

  • Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides
  • 雑誌 / 共著 / 2001年
    Clin. Cancer Res.
  • / Vol.7 3950-3962
  • 128

  • Multidrug resistance-associated protein 3 (MRP3) is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
  • 雑誌 / 共著 / 2001年
    Cancer Res.
  • / Vol.61 6459-6466
  • 129

  • Immunopotentiating effects of a glycoprotein from Chlorella vulgaris strain CK and its characteristics.
  • 単行本 / 分担執筆 / 2001年
    Bioactive Natural Products (Part F). Elsevier Science, Oxford.
  • / Vol.125 429-458
  • 130

  • Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides.
  • 雑誌 / 共著 / 2001年
    J. Orthopaed. Res.
  • / Vol.19 346-351
  • 131

  • Binding of a SART3 tumor-rejection antigen to a pre-mRNA splicing factor RNPS1: a possible regulation of splicing by the complex formation.
  • 雑誌 / 共著 / 2001年
    Int. J. Cancer
  • / Vol.93 623-628
  • 132

  • Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of metastatic cancer patients.
  • 雑誌 / 共著 / 2001年
    Eur. J. Immunol.
  • / Vol.31 323-332
  • 133

  • dentification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases.
  • 雑誌 / 共著 / 2001年
    Int. J. Cancer
  • / Vol.94 237-242
  • 134

  • Serum MAGE-4 protein in ovarian cancer patients.
  • 雑誌 / 共著 / 2000年
    Gynecologic Oncol.
  • / Vol.76 336-339
  • 135

  • A microfilament formation inhibitor, cytochalasin, strongly enhances the low affinity Fc-e receptor II (CD23) expression on the human monocyte-like cell line, U937.
  • 雑誌 / 共著 / 2000年
    J. Clin. Immunol.
  • / Vol.20 424-433
  • 136

  • Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the cytotoxic T lymphocytes.
  • 雑誌 / 共著 / 2000年
    J. Immunol.
  • / Vol.164 2565-2575
  • 137

  • Mouse homologue of human SART3 gene encoding tumor rejection antigen.
  • 雑誌 / 共著 / 2000年
    Jap. J. Cancer Res.
  • / Vol.91 239-247
  • 138

  • Establishment and epitope analysis of allo-specific cytotoxic T lymphocytes at a tumor site recognizing a spouse's HLA-A0206 molecule.
  • 雑誌 / 共著 / 2000年
    Am. J. Reprod. Immunol.
  • / Vol.43 167-173
  • 139

  • Chlorella vulgaris supernatant (CVS) reduces psychological stress-induced apoptosis in thymocytes of mice.
  • 雑誌 / 共著 / 2000年
    Int. J. Immunopharmacol
  • / Vol.22 877-885
  • 140

  • A unique monoclonal antibody mNI-11 rapidly enhances spread
  • 雑誌 / 共著 / 2000年
    J. Clin. Immunol.
  • / Vol.20 317-324
  • 141

  • CDw108 expression during T-cell development
  • 雑誌 / 共著 / 2000年
    Tissue Antigens.
  • / Vol.55 429-436
  • 142

  • Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor infiltrating lymphocytes of lung cancer.
  • 雑誌 / 共著 / 2000年
    Cancer Res.
  • / Vol.60 3550-358
  • 143

  • Identification of SART3-derived peptides capable of inducing HLA-A2-
  • 雑誌 / 共著 / 2000年
    Int. J. Cancer.
  • / Vol.88 633-639
  • 144

  • Tacrolimus (FK506) treatment of CD34+ hematopoietic progenitor cells promote the development of dendritic cells that drive CD4+ T cells
  • 雑誌 / 共著 / 2000年
    J. Leukocyte Biol.
  • / Vol.68 633-640
  • 145

  • Polymorphism of the 5’-flanking region of the tumor necrosis factor (TNF)-a gene and susceptibility to human T-cell lymphotoropic virus type I (HTLV-1) uveitis.
  • 雑誌 / 共著 / 1999年
    J. Infect. Dis.
  • / Vol.180 880-883
  • 146

  • Polymorphisms in the the 5’-flanking region of the tumor necrosis factor-a
  • 雑誌 / 共著 / 1999年
    Tissue Antigens.
  • / Vol.54 194-197
  • 147

  • Oral administration of hot water extracts of Chlorella vulgaris reduces IgE production against milk casein in mice.
  • 雑誌 / 共著 / 1999年
    Int. J. Immunopharmacol.
  • / Vol.21 311-323
  • 148

  • Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108.
  • 雑誌 / 共著 / 1999年
    J. Immunol.
  • / Vol.162 4094-4100
  • 149

  • Analysis of tumor necrosis factor-a production and polymorphisms of
  • 雑誌 / 共著 / 1999年
    Pediatrics Int.
  • / Vol.41 341-345
  • 150

  • Study of HLA-class I-restriction and directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer.
  • 雑誌 / 共著 / 1999年
    Cancer Immunol. Immunotherapy.
  • / Vol.48 147-152

  • 基本情報ページへ戻る


    久留米大学研究者紹介についてのお問合せ先
     現在、登録準備中の研究者もいます。内容については、随時更新することにしています。
     なお、研究者の個人情報(メールアドレス等)に関するお問い合わせはご遠慮ください。
     また、久留米大学研究者紹介の内容を無断転用することを禁止します。
     システムの制約上、対応できない文字に関しては、正式の表記ではない文字を使用しています。
    <医学部>
    総合企画部 産学官連携推進室 (久留米市旭町67)
    TEL:0942-31-7917 /  FAX:0942-31-7918
    kensuiアットマークkurume-u.ac.jp
    <文系学部>
    御井学舎事務部庶務課 (久留米市御井町1635)
    TEL:0942-43-4411 /  FAX:0942-43-0574
    mii-syomuアットマークkurume-u.ac.jp
    ※なお、取材等に関しましては、下記へお問い合わせください。
    総合企画部 広報室 (久留米市旭町67)
    TEL:0942-31-7511 / FAX:0942-31-7718
    kikaukukouhouアットマークkurume-u.ac.jp